CJC-1295 no DAC is a catalog designation for a GHRH-related peptide that must be distinguished from the albumin-binding, long-acting CJC-1295 used in published human trials.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
GHRH analogue; identity qualification required
The catalog also uses the alias Mod GRF, but that name alone does not confirm a complete sequence or terminal chemistry. The original CJC-1295 research compound contained a modified GHRH(1–29) sequence plus an albumin-reactive attachment. Removing that attachment changes the molecule; the no-DAC designation therefore cannot identify it as the same trial substance.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
For a correctly identified modified GHRH peptide, the intended research target is the pituitary GHRH receptor and the resulting GH–IGF-1 axis. Albumin attachment chiefly changes exposure and persistence. Receptor-class similarity does not make the concentration-time profile or measured endocrine effects interchangeable between attached and unattached analogues.
The original development study examined albumin conjugates in pituitary-cell assays and rats. It demonstrates why the reactive attachment matters, rather than supplying stability measurements for an unspecified no-DAC preparation. [1]
Controlled human trials found prolonged endocrine responses to long-acting CJC-1295. Those data concern the albumin-binding compound. Its multi-day exposure and hormone-response results should not be presented as measurements of the catalog's no-DAC material. [2]
A human follow-up study evaluated GH pulsatility during sustained CJC-1295 stimulation. Pulses persisted while basal secretion increased, illustrating why average hormone levels and pulse structure are separate endpoints. Again, the tested analogue contained the albumin-binding functionality. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The cited papers are primary studies of long-acting CJC-1295, not direct validation of this catalog designation. They provide background on GHRH analogue design and endocrine measurements. None establishes efficacy or pharmacokinetics for the specific no-DAC material offered here.
Confirm the amino-acid sequence, substitutions, terminal groups, and absence of the albumin-reactive moiety before matching this entry to a paper. Claims about duration, clinical outcomes, or safety cannot be transferred from the DAC compound merely because both names include CJC-1295.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Defines the albumin-reactive CJC-1295 structure; related-compound evidence only for a no-DAC listing.
Studied long-acting albumin-binding CJC-1295; its duration and endocrine results do not apply automatically to no-DAC material.
Physiology study of the albumin-binding analogue, not an unattached modified GHRH peptide.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
